Genetic study of a brain condition called CAA
Part of Blood & lymphatic, Brain & nervous system clinical trials.
This study looks at the genetic causes of cerebral amyloid angiopathy (CAA), a condition where proteins build up in small brain blood vessels. It aims to better understand the disease and may help guide future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with definite or probable CAA based on standard imaging criteria.
- Your first symptoms started before age 66.
- You have already had genetic testing that did not find a mutation in the APP gene.
- You agree to let researchers use your stored genetic samples for further study.
- You are covered by a national health insurance plan.
- You are not a minor and are not currently in legal custody.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks for genetic causes of hard-to-diagnose autoinflammatory diseases or a related condition called AA amyloidosis. It aims to find answers for people whose condition does not fit any known type, by studying their genes and medical history.
This study looks at genetic (inherited DNA) factors in people with certain abnormal blood vessel connections in the brain or spinal cord. It may help researchers understand why these malformations happen and how they might behave over time.
This study looks at brain MRI scans in people with cerebral amyloid angiopathy (a condition where amyloid builds up in brain blood vessels). The goal is to search for “biomarkers,” or measurable scan features, to better understand and detect the disease in some people before symptoms or during symptoms.
This Phase 2 study tests AMDX-2011P to see if it can help people with cerebral amyloid angiopathy (CAA), a condition where abnormal protein affects blood vessels in the brain. You may be able to join if you have confirmed or likely CAA and a recent brain MRI showing changes from CAA.
This study tests whether the drug LXB (sodium oxybate) can help clear abnormal protein buildup in the brain's small blood vessels (CAA). Participants will take LXB nightly for 8 weeks and have MRIs and spinal taps to measure changes.
This trial is looking at how brain “small blood vessel disease” changes over time and what outcomes to expect. If you have certain symptoms or scan findings from this condition, your care team may compare your prognosis to help guide future treatment planning.
Hear when a new Cerebral Amyloid Aβ Angiopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.